Markets

SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event

Oct 28, 2026 · 08:37 AM ET· updated 1h ago

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

Why It Matters

SELLAS finished testing a new cancer medicine with good results. When a company passes these tests, it shows the medicine might actually help real patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

SLS10.29

-1.88 (-15.49%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.